Physician profile
Eileen Chang
NPI 1063529196
$9,854.66
in general payments reported to CMS, 2019-2025
61 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $1,221 · 2021: $3,039 · 2022: $1,284 · 2023: $802 · 2024: $1,085 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,280.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,268.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $969.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $761.58 | 2019-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $528.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.83 | 2019-2025 | Jardiance |
| Amgen INC. | $431.95 | 2019-2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $357.45 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $333.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $309.46 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $264.77 | 2019-2025 | |
| Abbott Laboratories | $183.92 | 2020-2024 | Proclaim, Freestyle Libre 3 |
| Astellas Pharma US INC | $167.66 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $156.46 | 2022 | |
| Exact Sciences Corporation | $143.22 | 2023-2025 | Cologuard Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.